UptimeAI Inc., a pioneering force in the intersection of artificial intelligence and heavy industry, is thrilled to announce the successful closing of a $14 million funding round aimed at enhancing operational efficiency across the industrial landscape. This fresh capital will enable UptimeAI to further develop its innovative platform that uniquely blends advanced AI technology with over 200 years of cumulative subject matter expertise in heavy industry. The company’s state-of-the-art solutions are designed to provide real-time insights into the interrelations between upstream and downstream equipment, allowing businesses to adapt to changes, swiftly identify potential problems, and receive prescriptive diagnoses akin to the advice of a seasoned human expert. The funding will be instrumental in scaling UptimeAI's operations, expanding its team of AI specialists and industry veterans, and accelerating the deployment of its technology across various sectors, including manufacturing, oil and gas, and utilities. With this investment, UptimeAI is poised to refine its algorithms, enhance data integration capabilities, and ultimately empower companies to achieve unprecedented levels of operational uptime and efficiency. As UptimeAI continues to revolutionize how industries utilize data to improve their processes, we invite potential partners and clients to explore collaboration opportunities. For inquiries and further information, please contact us at info@uptimeai.com or call +1(415)-935-1195. With this funding round, UptimeAI reaffirms its commitment to driving intelligent solutions that foster sustainable growth in heavy industry.
UptimeAI Inc. Secures $14 Million in Series A Funding for Groundbreaking AI-Powered Heavy Industry Solutions
Recently funded · $14.0M Series aArtificial Intelligence
Get the full UptimeAI Inc. company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Mach42
Mach42â„¢ is a spinout company from Oxford University, delivering the next step-change in simulation acceleration, an early-stage software company developing state-of-the-art machine learning and Artificial Intelligence technology to simplify, automate, and accelerate simulation tasks. We leverage proprietary neural network technology to accelerate expensive calculations, and we do it with minimal data and high accuracy, providing many orders of magnitude speedup in verification acceleration. Our platform is already delivering a substantial competitive advantage to our early customers.
$9.1M Seed
today
Transcripta Bio
We are focused on drug discovery at unprecedented speed and scale, with lower risk and higher certainty across multiple diseases in parallel. With data from hundreds of millions of experiments, we have mapped the effects of thousands of compounds on gene expression to discover new therapies. Our Drug-Gene Atlas maps molecular structure and drug action to the whole cell transcriptome, revealing therapeutic candidates that rebalance gene expression to treat disease. Our proprietary artificial intelligence modeling suite, Conductor AI, used our Drug-Gene Atlas to discover and predict the effects of new drugs at transcriptome scale.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Transcripta Bio United States | Series a | $24.0M | today |
| 2 |  Assured United States | Series a | $19.0M | today |
.png&w=3840&q=75)
